Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Minerva Anestesiol ; 87(12): 1330-1337, 2021 12.
Article in English | MEDLINE | ID: covidwho-1464162

ABSTRACT

BACKGROUND: The majority of prevalence studies on deep vein thrombosis (DVT) in severe COVID-19 patients are retrospective with DVT assessment based on clinical suspicion. Our aim was to prospectively and systematically estimate the occurrence of DVT in critically-ill mechanically-ventilated patients, and to identify potential risk factors for DVT occurrence and mortality. METHODS: All patients with COVID-19 admitted to our 45 beds in the Intensive Care Unit (ICU) between March 6, 2020, and April 18, 2020, requiring invasive ventilatory support were daily screened for DVT with lower extremities and jugular veins ultrasonography. Univariate and multivariable logistic regression models were performed in order to identify predictors of DVT and mortality. RESULTS: Seventy-six patients were included in the final analysis (56 men, mean age 67 years, median SOFA=7 points, median SAPS II=41 points, median PaO2/Fi02=10.8 kPa). The period prevalence of DVT was 40.8%. Thirty-one DVTs were diagnosed. Twenty-five DVTs (80.6% of total DVTs) were catheter-related, mainly in the jugular veins. Twenty-six DVTs (83.9%) occurred in patients receiving enhanced antithrombotic prophylaxis. No independent variable was predictive of DVT occurrence. Twenty-eight patients (36.8%) died during the ICU stay. Age and SOFA score were independently associated with mortality. CONCLUSIONS: A high number of critically-ill mechanically-ventilated COVID-19 patients developed a DVT. The majority of DVTs were catheter-related and occurred under intensive prophylactic anticoagulation. Routine ultrasound of the jugular veins should be suggested in this patient population, and in particular in presence of a central venous catheter.


Subject(s)
COVID-19 , Venous Thrombosis , Aged , Critical Illness , Humans , Male , Prevalence , Retrospective Studies , Risk Factors , SARS-CoV-2 , Venous Thrombosis/epidemiology , Venous Thrombosis/etiology
4.
Artif Organs ; 45(7): 754-761, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-978685

ABSTRACT

Noninvasive continuous positive airway pressure (NIV-CPAP) is effective in patients with hypoxemic respiratory failure. Building evidence during the COVID-19 emergency reported that around 50% of patients in Italy treated with NIV-CPAP avoided the need for invasive mechanical ventilation. Standard NIV-CPAP systems operate at high gas flow rates responsible for noise generation and inadequate humidification. Furthermore, open-configuration systems require a high concentration of oxygen to deliver the desired FiO2 . Concerns outlined the risk for aerosolization in the ambient air and the possible pressure drop in hospital supply pipes. A new NIV-CPAP system is proposed that includes automatic control of patient respiratory parameters. The system operates as a closed-loop breathing circuit that can be assembled, combining a sleep apnea machine with existing commercially available components. Analytical simulation of a breathing patient and simulation with a healthy volunteer at different FiO2 were performed. Inspired and expired oxygen fraction and inspired and expired carbon dioxide pressure were recorded at different CPAP levels with different oxygen delivery. Among the main findings, we report (a) a significant (up to 30-fold) reduction in oxygen feeding compared to standard open high flow NIV-CPAP systems, to assure the same FiO2 levels, and (b) a negligible production of the noise generated in ventilatory systems, and consequent minimization of patients' discomfort. The proposed NIV-CPAP circuit, reshaped in closed-loop configuration with the blower outside of the circuit, has the advantages of minimizing aerosol generation, environmental contamination, oxygen consumption, and noise to the patient. The system is easily adaptable and can be implemented using standard CPAP components.


Subject(s)
COVID-19/therapy , Continuous Positive Airway Pressure/instrumentation , Lung/virology , Noise/prevention & control , Noninvasive Ventilation/instrumentation , Oxygen/administration & dosage , SARS-CoV-2/pathogenicity , Ventilators, Mechanical , Aerosols , COVID-19/physiopathology , COVID-19/transmission , COVID-19/virology , Computer Simulation , Continuous Positive Airway Pressure/adverse effects , Equipment Design , Filtration/instrumentation , Humans , Lung/physiopathology , Noise/adverse effects , Noninvasive Ventilation/adverse effects , Numerical Analysis, Computer-Assisted , Oxygen/adverse effects
5.
ClinicalTrials.gov; 18/09/2020; TrialID: NCT04567927
Clinical Trial Register | ICTRP | ID: ictrp-NCT04567927

ABSTRACT

Condition:

SARS Virus

Intervention:

Other: Ultrasonography

Primary outcome:

Period prevalence of deep vein thrombosis (DVT)

Criteria:


Inclusion Criteria:

- patients admitted to the Intensive Care Unit

- laboratory confirmed SARS-CoV-2 infection

- invasive respiratory support

Exclusion Criteria:

- none


SELECTION OF CITATIONS
SEARCH DETAIL